Fisher Wallace Laboratories is a company focused on developing and commercializing wearable brain stimulation technology for the treatment of anxiety, depression, insomnia, and other neuropsychiatric and cognitive disorders. Their device, known as the Fisher Wallace Stimulator, uses Transcranial Alternating Current Stimulation to modulate brain function and cognitive processes. This technology is designed to be used safely in conjunction with medication or as a standalone therapy.
The device is used for 20 minutes twice a day, once after waking up and once before bed. For those treating insomnia only, it is used once a day before bed. The device is known for its ease of use and can be integrated into a normal routine. Most patients do not feel the stimulation, and it has been used by over 100,000 people in the United States.
Fisher Wallace Laboratories is committed to increasing access to rapid and safe mental healthcare. Their Version 2.0 wearable, OAK, is expected to be commercialized in 2025 for the treatment of anxiety and depression. The company has conducted significant clinical research, including a 255-subject, triple-blind, randomized, controlled trial that showed significant reduction in depression within the first week of treatment.
The device has been on the market for decades without any reports of long-term negative effects. It is important to note that patients with implanted electronic medical devices, such as pacemakers, should not use the Fisher Wallace Stimulator. The company is also engaged in obtaining regulatory approval for their new device, OAK, which was designed in collaboration with teams behind Beats, Nest, and the HoloLens.
Fisher Wallace Laboratories aims to provide a convenient and powerful solution for mental health treatment, making it a notable player in the field of wearable medical devices.